Table 1 Samples cross-reacting to low-risk and unconfirmed genotypes

Overall

  Positive test results, Total population (N = 5022)

1505

1024 (20.4 %)

1345 (26.8 %)^a

838 (16.7 %)^a

  Positive test results, Primary screening population age 30–65 years (N = 2859)

553

335 (11.7 %)

464 (16.2 %)

270 (9.4 %)

  Positive test results, Referral population (N = 887)

499

401 (45.2 %)

453 (51.1 %)

332 (37.4 %)

Cross-reactivity to low-risk genotypes

  Cross-reacting samples

157

109

62

35

  Absolute cross-reactivity

–

109/5022 (2.2 %)

62/5022 (1.2 %)

35/5022 (0.7 %)

  Absolute cross-reactivity (vs. HC2)

–

1 (reference)

0.6 (0.4 to 0.8)

0.3 (0.2 to 0.5)

  Relative cross-reactivity

–

109/1024 (10.6 %)

62/1345 (4.6 %)

35/838 (4.2 %)

  Relative cross-reactivity (vs. HC2)

–

1 (reference)

0.4 (0.3 to 0.6)

0.4 (0.3 to 0.6)

  Cross-reacting samples

61

43

20

13

  Absolute cross-reactivity

–

43/2859 (1.5 %)

20/2859 (0.7 %)

13/2859 (0.5 %)

  Absolute cross-reactivity (vs. HC2)

–

1 (reference)

0.5 (0.3 to 0.8)

0.3 (0.2 to 0.6)

  Relative cross-reactivity

–

43/335 (12.8 %)

20/464 (4.3 %)

13/270 (4.8 %)

  Relative cross-reactivity (vs. HC2)

–

1 (reference)

0.3 (0.2 to 0.6)

0.4 (0.2 to 0.7)

  Cross-reacting samples

58

47

16

8

  Absolute cross-reactivity

–

47/887 (5.3 %)

16/887 (1.8 %)

8/887 (0.9 %)

  Absolute cross-reactivity (vs. HC2)

–

1 (reference)

0.3 (0.2 to 0.6)

0.2 (0.1 to 0.4)

  Relative cross-reactivity

–

47/401 (11.7 %)

16/453 (3.5 %)

8/332 (2.4 %)

  Relative cross-reactivity (vs. HC2)

–

1 (reference)

0.3 (0.2 to 0.5)

0.21 (0.1 to 0.4)

  Absolute cross-reactivity (95 % confidence interval)

–

0.3 (0.2 to 0.4)

0.4 (0.2 to 0.7)

0.5 (0.2 to 1.2)

  Relative cross-reactivity (95 % confidence interval)

–

1.1 (0.7 to 1.6)

1.2 (0.6 to 2.3)

2.0 (0.8 to 4.8)

Cross-reactivity to unconfirmed genotypes

  Cross-reacting samples

223

49

162

56

  Absolute cross-reactivity

–

49/5022 (1.0 %)

162/5022 (3.2 %)

56/5022 (1.1 %)

  Absolute cross-reactivity (vs. HC2)

–

1 (reference)

3.3 (2.4 to 4.5)

1.1 (0.8 to 1.7)

  Relative cross-reactivity

–

49/1024 (4.8 %)

162/1345 (12.0 %)

56/838 (6.7 %)

  Relative cross-reactivity (vs. HC2)

–

1 (reference)

2.5 (1.8 to 3.4)

1.4 (1.0 to 2.0)

  Total positive test results

553

335 (11.7 %)

464 (16.2 %)

270 (9.4 %)

  Cross-reacting samples

126

30

87

36

  Absolute cross-reactivity

–

30/2859 (1.0 %)

87/2859 (3.0 %)

36/2859 (1.3 %)

  Absolute cross-reactivity (vs. HC2)

–

1 (reference)

2.9 (1.9 to 4.4)

1.2 (0.7 to 1.9)

  Relative cross-reactivity

–

30/335 (9.0 %)

87/464 (18.8 %)

36/270 (13.3 %)

  Relative cross-reactivity (vs. HC2)

–

1 (reference)

2.1 (1.4 to 3.1)

1.5 (0.9 to 2.4)

  Total positive test results

499

401 (45.2 %)

453 (51.1 %)

332 (37.4 %)

  Cross-reacting samples

37

9

27

8

  Absolute cross-reactivity

–

9/887 (1.0 %)

27/887 (3.0 %)

8/887 (0.9 %)

  Absolute cross-reactivity (vs. HC2)

–

1 (reference)

3.0 (1.4 to 6.3)

0.9 (0.3 to 2.3)

  Relative cross-reactivity

–

9/401 (2.2 %)

27/453 (6.0 %)

8/332 (2.4 %)

  Relative cross–reactivity (vs. HC2)

–

1 (reference)

2.3 (1.3 to 5.6)

1.1 (0.4 to 2.8)

  Absolute cross-reactivity (95 % confidence interval)

–

1.0 (0.5 to 2.2)

1.0 (0.7 to 1.5)

1.4 (0.7 to 3.0)

  Relative cross-reactivity (95 % confidence interval)

–

4.0 (1.9 to 8.3)

3.1 (2.1 to 4.7)

5.5 (2.6 to 11.7)